What LillyDirect Actually Costs, Product by Product

LillyDirect is Eli Lilly selling its own drugs to patients without a wholesaler, a retail pharmacy or a benefit manager in between. As of August 2026 the storefront no longer lives on its own domain: a request to lillydirect.com returns a 301 redirect to lilly.com/lillydirect, which is where the current prices are published.¹

What follows is everything it prices, everything it does not, and the two pieces of fine print that change the annual total most.

The three products with a published self-pay price

Zepbound® (tirzepatide), single-patient-use KwikPen or single-dose vial — $299/month at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5 and 15 mg. The pen and the vial carry identical prices at every tier; the vial is noted as available exclusively through LillyDirect. Needles and syringes are a separate purchase. A month is 28 days.²

Mounjaro® (tirzepatide) — "Starting at $499/month", printed against all six strengths from 2.5 mg to 15 mg. One price, no ladder.³

Foundayo™ (orforglipron), tablets — $149/month at 0.8 mg, $199 at 2.5 mg, and $299 at 5.5, 9, 14.5 and 17.2 mg. The 14.5 and 17.2 mg tiers hold the $299 only on a refill within 45 days; otherwise the regular price is $349. A month is 30 days.⁴

Foundayo is the cheapest branded entry price on the site, and it is not a small drug: it was approved as NDA 220934 on 1 April 2026, with a supplement approved on 4 August 2026.⁵ Its label indicates it for weight reduction and long-term weight maintenance in adults with obesity, or overweight with at least one weight-related comorbid condition.⁶

The eight products listed with no price at all

Trulicity® (dulaglutide), Emgality®, the Humalog® family, the Humulin® family, Basaglar®, Rezvoglar® and Lyumjev® all appear in the storefront's available-medicines list with their strengths shown and no self-pay figure beside them.¹

That is worth saying plainly rather than reading as an oversight. As of August 2026, LillyDirect's published catalogue carries a self-pay price for three of the eleven medicines it lists. If you are pricing an insulin, this site will not tell you what it costs before you start an order.

One storefront, two definitions of a month

Zepbound's terms define a month as 28 days.² Foundayo's define it as 30 days.⁴

That is not pedantry, it is the single largest arithmetic trap on the site:

Zepbound at $449, 28-day months → 365 ÷ 28 ≈ 13.0 fills a year → $5,837.

Foundayo at $299, 30-day months → 365 ÷ 30 ≈ 12.2 fills a year → $3,637 at twelve fills, $3,936 at thirteen.

Twelve times the monthly price understates a year of Zepbound by roughly $449 — one entire extra fill that nobody quotes.

The 45-day refill clock, and what it binds

Two of the three priced products attach a refill condition, and one does not.

Zepbound's $299, $399 and $449 hold on a refill within 45 days of the last delivery. Outside the window, Lilly's regular prices of $499 to $699 apply.² At 10 mg that is a $250 swing on a single fill.

Foundayo's top two tiers work the same way, at a smaller magnitude: $299 with a refill inside 45 days, $349 without.⁴

Mounjaro's $499 carries no refill condition on the page we read; its footnote says only "For self-pay. Prescription required. Terms apply. Additional taxes and fees may apply."³

What the ladder tracks on the label

Foundayo is the clearest case on the site of a price ladder built directly on a dosing schedule. The label starts at 0.8 mg once daily, increases to 2.5 mg after at least 30 days, then to 5.5 mg after at least 30 more, with 9, 14.5 and 17.2 mg available at 30-day intervals thereafter and 17.2 mg the maximum.⁶

Six label steps, six price rows, matched one to one, with the price flattening at $299 from the third step onward. Priced at one step per fill, the first twelve months come to $149 + $199 + (10 × $299) = $3,338.

Where these prices sit against what a pharmacy pays

CMS's NADAC survey reports what retail pharmacies pay wholesalers. On the file dated 5 August 2026, rates effective 22 July⁷:

Mounjaro 10 mg pen — $538.60429 per mL × 0.5 mL × 4 pens = $1,077.21 a month, against LillyDirect's $499.

Zepbound KwikPen 15 mg per dose — $279.26406 × 2.4 mL = $670.23, against LillyDirect's $449.

Zepbound 10 mg single-dose pen — $526.15096 × 0.5 × 4 = $1,052.30, against the same $449.

In each case the direct price is below the acquisition cost of the equivalent box through the normal channel. That is the whole proposition of a manufacturer storefront, and it is why the LillyDirect number is usually the one to beat before you compare anything else. Our LillyDirect review grades the storefront itself rather than the price sheet. Our Zepbound vs Wegovy comparison prices both manufacturers' direct channels against each other, and what NovoCare Pharmacy costs does the same job for Novo Nordisk's storefront.

Where it does not win

Buying the same branded Zepbound through a telehealth membership adds a recurring care fee on top of an identical drug price. Ro charges $39 then $149 a month for that layer, taking a $449 medication line to $598 all-in.⁸ Over a year that is $1,829 more for the same product — the arithmetic is in compounded tirzepatide vs branded Zepbound, and the bill is dismantled in our Ro review.

What we could not establish

We could not price the eight unpriced medicines, because no self-pay figure for them appears on LillyDirect's published catalogue as of August 2026. That is a statement about what is on the page, not a claim that no price exists behind an account.

We could not verify what LillyDirect charges for the needles and syringes its Zepbound terms require, because no figure for them is published alongside the drug price.

And we could not price any of these through insurance. Lilly publishes savings-card terms rather than plan prices, and those cards state that they expire and savings end on 31 December 2026.⁹

Zepbound®, Mounjaro®, Trulicity®, Humalog®, Humulin®, Basaglar®, Rezvoglar®, Lyumjev®, Emgality® and Foundayo™ are trademarks of Eli Lilly and Company. Doseworth is not affiliated with Eli Lilly.